The biopharmaceutical company, Amicus Therapeutics, announced plans to expand to Greater Philadelphia and open a new Global Research and Gene Therapy Center that will continue their focus on rare and orphan diseases.
The revolutionary center will be located at uCitySquare in the University City neighborhood of Philadelphia; an area that has become a hub for innovation, entrepreneurship, and life sciences.
“It’s a big deal for us, and I hope for Philadelphia, as well,” said CEO of Amicus Therapeutics, John F. Crowley.
Amicus anticipates collaborating with our region’s top gene therapy researchers at University of Pennsylvania, Penn Medicine, and Drexel University, making uCitySquare the ideal location.
Amicus will be the flagship of uCitySquare and occupy three stories and 75,000 square feet of new construction at 3675 Market Street. This expansion will add approximately 200 jobs and is expected to open in late 2019.
Numerous transformation projects have taken place in uCitySquare recently. Two years ago, Cambridge Innovation Center (CIC), a previously Boston-based real estate services company, moved to uCitySquare. The company has since been developing spaces for entrepreneurs to improve and accelerate their business in Greater Philadelphia.